Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurora Cannabis Inc T.ACB

Alternate Symbol(s):  T.ACB.WS.U | ACB

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution, and sale of cannabis related products in Canada and internationally. The Company’s segments include Canadian Cannabis, European Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being and Greybeard, as well as CBD brands, Reliva and KG7. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol and CraftPlant. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia, and Odense, Denmark. The Company is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets.


TSX:ACB - Post by User

Bullboard Posts
Post by greggegenon Jun 05, 2018 1:48pm
293 Views
Post# 28127227

Aurora leading sector consolidation

Aurora leading sector consolidationI invested in Aurora because it's hard to ignore the sector today and they seem to me to have a solid management team with an impressive strategy and recent acquisitions seem to have been well considered.  Medleaf offers a solid product slate, r&d depth and more market reach....so IMHO a very attractive value play IMHO. But geesh...they really paid up for it...arguably too much on current metrics.  Growth pressures will be enormous for the foreseeable future.  But I have no real confidence about how to predict growth in this sector...I want to believe that the demand is immense both recreationally and that medicinal/clinical applications will ultimately have a profound impact on future health care sectors.  Suspect we might see some nice bumps along the way but I guess it will take time for rewards to flow through decisively for shareholders?.  This article is interesting:
https://www.forbes.com/sites/greatspeculations/2018/06/04/why-did-aurora-cannabis-pay-such-a-high-price-for-medreleaf-corp/2/   Cheers, GE
Bullboard Posts